Resveratrol is a plant-derived polyphenol suggested to have many beneficial health effects, including antioxidant, anti-inflammatory, anti-proliferative, proapoptotic, and anti-angiogenic. It is even specu-lated that uptake of resveratrol by red wine consumption could be behind the socalled French paradox the lower incidence of cardiovascular diseases in the French population. These properties, together with good absorption and tolerance, would make it an attractive agent in prostatic diseases, especially in cancer prevention and treatment. Material and methods. MEDLINE search (keywords "prostate res-veratrol") resulted in 39 research papers published since 2007. It has been shown that resveratol down-regulate androgen receptor expression, inhibit proliferation, and promote apop-tosis in prostate cancer cell lines and enhance their sensitivity to ionizing radiation. Several studies on animal prostate cancer development also suggest that resveratrol is able do delay or prevent carcino-genesis in prostate. Despite these promising results, there is no proof of any therapeutic properties of resveratrol in prostate diseases from human clinical trials nor any information about ongoing trials in this field. Conclusions. Resveratrol is produced and sold as a nutritional supplement, there is not enough clinical evidence to justify a recommendation for the administration of resveratrol in humans at present.
INTRODUCTION
Resveratrol (trans-3, 4', 5-trihydroxystilbene, C 14 H 12 O 3 ) is a plant-derived polyphenolic phytoalexin produced in response to environmental stress such as vicissitudes in climate, exposure to ozone, sunlight and heavy metals, and infection by pathogenic microorganisms. Resveratrol exists in both cis-and trans-stereoisomeric forms, the predominant trans-isomer is the biologically active one [1, 2, 3] . Exposure to heat and ultraviolet radiation can cause trans-resveratrol to isomerize to the cis-resveratrol. It is primarily found in the skin of grapes as well as in other fruits and plants, such as raspberries, blueberries, mulberries, Scots pine, Eastern white pine, and knotweed [1, 4] . It is speculated that uptake of resveratrol by red wine consumption could be behind the so-called French paradox -whereby the French population, in spite of a rather fatty diet, has a lower incidence of cardiovascular disease [1] . Resveratrol is also produced by chemical and biotechnological synthesis and sold as a nutritional supplement. It is well absorbed upon oral ingestion and metabolized to sulfate and glucuronate [1, 2] . Resveratrol has been reported do have a wide range of effects beneficial for health, including cardioprotective, neuroprotective, and immunomodulatory function as well as improving insulin sensitivity, but in relation to prostatic diseases, the following ones are the most interesting: anticancer -resveratrol has been reported to have antiproliferative and proapoptotic effects on prostate cancer cell lines LNCaP, DU-145, and PC-3; it also potentiates the effect of ionizing radiation and chemotherapeutic agents; potential chemopreventive properties; antiinflammatory and antioxidant functions, which may be useful in treatment of prostate inflammation; and also play a role in chemoprevention, as a positive correlation between prostatitis and prostate cancer risk has been reported [5, 6] . Prostate cancer (PCa), being one of the most common malignancies and a major cause of cancer-related death in men, is a considerable health problem, especially in ageing populations, since it is typically diagnosed in men over the age of 50 [6, 7] . All these, together with its long latency, make PCa an attractive target for chemopreventive interventions [4, 6] . There is also a considerable amount of epidemiological data suggesting that certain nutritional factors may influence PCa occurrence [6, 8] . Consequently, several PCa risk reduction studies were conducted, but only in two of them -PCPT (finasteride) and RE-DUCE (dutasteride) -a reduction of PCa incidence was observed. The most important endpoint -the reduction of mortality, however, was not reached in either of them [9] . This may be partially due to the slow natural course of the disease, which would require an ideal observation period of around 20 years. In this paper, recently published research articles on the application of resveratrol in prostate diseases have been reviewed in order to shed light on the evidence justifying its application in prevention and treatment of prostate diseases.
Mechanism of action
Resveratrol induces a broad range of effects on cell phenotype. Numerous studies have reported resveratrol to cause cell growth inhibition, modulation of cell cycle, induction of apoptosis in many different cell lines, including PCa ones [2, , and induction of differentiation in certain cell types [27, [46] [47] [48] [49] . All these are important in cancer treatment and are exerted by modulating a complex range of cellular processes, including: receptor function, transduction pathways, and transcription factor activity. The detailed description of all the documented resveratrol mechanisms of action would exceed this paper. Apart from these, resveratrol has been reported to exhibit other properties that may be useful in cancer treatment: inhibition of tumor invasion and angiogenesis as well as increase of radiosensitivity and chemosensitivity. The expression of matrix metalloproteases (MMPs) correlates with tumor invasion and metastasis, which make them attractive pharmaceutical targets in cancer treatment [50] . Resveratrol reduced the expression of MMP-2 and MMP-9 in certain cell lines [51] [52] [53] [54] [55] and decreased the level of vascular epithelial growth factor (VEGF), a protein crucial for angiogenesis and maintaining tumor growth, thus inhibiting angiogenesis [56] [57] [58] [59] [60] . Another interesting property of resveratrol is its ability to increase prostate cancer cell lines sensitivity to ionizing radiation, which has a potential for clinical application in combination with radiotherapy -an important treatment in PCa [17, 19, 20, 43] . Resveratrol has also been shown to sensitize human cancer cell lines, including prostate carcinoma, to such chemotherapeutic agents as doxorubicin, cytarabine, actinomycin D, taxol, and methotrexate by down-regulating survivin expression and increasing apoptosis [61] . Inflammation has been proven to be a significant factor in the initiation/progression stages of cancer development by inducing oxidative damage and promoting cell growth [62, 63] . Cyclooxygenase-2 (COX-2) catalyzes the conversion of free arachidonic acid to prostaglandins, which can stimulate cell proliferation, promote angiogenesis, and suppress apoptosis all of which promote malignancy [64] [65] [66] .
Resveratrol expresses anti-inflammatory activity by directly inhibiting COX-2 activity and suppressing NFκB by up-regulating MKP5 [44, 67] .
Review of current studies
Resveratrol and its mechanisms of action have been intensively investigated and a large amount of evidence suggesting that it may be a promising molecule in both PCa treatment and prevention has been collected. MEDLINE search (keywords "prostate resveratrol") resulted in 39 research papers published since 2007 -the results of which are presented in Table 1 . Surprisingly, a considerable number of in vitro and a few animal model experiments have been performed, with lack of human clinical trials. There are currently no published demonstrations of therapeutic or protective effects of resveratrol in appropriately designed clinical trials [64] . Web page http:// www.clinicaltrials.org reported five ongoing trials of resveratrol in cancer, but none in prostate disease. The results of several resveratrol pharmacokinetics and metabolism studies in humans, however, have already been published and despite good absorption upon oral administration, poor bioavailability of unchanged resveratrol indicates that it would be difficult to achieve concentrations proven to be effective in in vitro studies [68, 69] . Additionally, a study by Klink et al., indicates that resveratrol may actually worsen the survival in certain prostate cancer xenograft models [70] . Among 38 research papers on resveratrol in prostate diseases published between 2007 and 2012, 35 were performed on cell lines and nine on in vivo models (five transgenic models of PCa development and five PCa xenografts). Seven studies concentrated on the role of androgen receptor and four on enhancement of radiosensitivity (Table 1) . A short characteristic of PCa cell lines most commonly used in experiments listed in Table 1 -their androgen sensitivity, p53 and PTEN (proteins important in mechanism of action of resveratrol in PCa cells) are presented in Table 2 . TRAMP, TRAP, and SV-40 Tag are transgenic animal models of PCa development -animals programmed to develop prostate cancer -were used to assess potential chemopreventive properties of resveratrol.
CONCLUSIONS
The anti-cancer potential of resveratrol has been well documented in many in vitro and in vivo studies. Down-regulation of androgen receptor and synergy with flutamide, as well as enhancement of radiosensitivity are the most interesting properties in treatment of prostate cancer.
Resveratrol has displayed a potential as prostate cancer chemoprevention in both in vitro and animal model studies.
Resveratrol is well-tolerated, but an optimal dose has not yet been determined. There are no results from human clinical trials on therapeutic effects of resveratrol in prostate diseases. Despite promising results from many studies, published evidence is not strong enough to justify chronic administration of resveratrol to humans. 
